
Dropping GLP-1 coverage leaves workers ‘terrified’
A costly class of weight-loss drugs is colliding with employers’ balance sheets, and many workers are finding themselves stuck in the middle, NBC News reports. Shannon Pettypiece explains how companies that once embraced GLP-1 drugs like Wegovy and Zepbound are now reducing their coverage as healthcare costs rise. In a Business Group on Health survey, the share of large employers covering GLP-1 for weight loss fell from 72% in 2025 to 60% this year, with none of the 127 employers planning to add the benefit again. Big names cutting or reducing their coverage include Starbucks, UPS, PepsiCo, University of Louisville, Mass General Brigham and Comcast.
Executives argue that drugs are among the fastest-rising expenses and that cuts are needed to keep health plans affordable, while doctors and obesity advocates warn that the sudden end of coverage for what they view as chronic disease treatment creates a two-tiered system: people who can afford several hundred dollars a month in out-of-pocket expenses, and those who cannot. Patients describe resorting to tapering programs, increasing doses, or even stopping altogether, telling Pettypiece that they are “terrified” of what will happen to their health. For the real-world stories, hard numbers and employer rationales, read Pettypiece’s full article on NBC News.
Gn Health